Failure to down-regulate Bcl-2 protein in thymic germinal center B cells in myasthenia gravis

Eur J Immunol. 1997 Apr;27(4):805-9. doi: 10.1002/eji.1830270402.

Abstract

The most unusual characteristic of myasthenia gravis (MG) is that the thymus has germinal centers (GC). Cultured thymic lymphocytes from MG patients spontaneously produce anti-acetylcholine receptor antibodies, indicating that autoreactive B cells have escaped negative selection. To investigate the underlying mechanism, we examined the expression of the apoptosis-related protein Bcl-2 in GC B cells (defined as CD19+ CD38+ cells) in the thymus in 14 MG patients using three-color flow cytometry. GC in MG patients did not show the normal down-regulation of Bcl-2 (the frequency of Bcl-2+ GC B cells in the MG thymus and in control tonsils 54.3 +/- 16.2% versus 20.6 +/- 8.0%; mean +/- SD. p < 0.0001). In contrast, Bcl-2 in GC in the mediastinal lymph nodes from four patients was down-regulated to a relatively normal level. Using the terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end-labeling (TUNEL) method to detect DNA fragmentation in situ, the frequency of TUNEL+ cells in GC in the MG thymus was lower than in control tonsils. These results suggest that autoreactive B cells which normally undergo apoptosis in GC may survive because of Bcl-2 up-regulation in this unusual location.

MeSH terms

  • Adolescent
  • Adult
  • Apoptosis
  • B-Lymphocytes / metabolism*
  • Child
  • Child, Preschool
  • Down-Regulation / immunology*
  • Female
  • Germinal Center / cytology
  • Germinal Center / metabolism*
  • Humans
  • Lymph Nodes / metabolism
  • Lymphocyte Count
  • Male
  • Mediastinum
  • Middle Aged
  • Myasthenia Gravis / immunology*
  • Myasthenia Gravis / metabolism
  • Proto-Oncogene Proteins c-bcl-2 / biosynthesis*
  • Thymus Gland / cytology
  • Thymus Gland / metabolism*

Substances

  • Proto-Oncogene Proteins c-bcl-2